Currently, the population aging is becoming increasingly severe, and the incidence of age-related macular degeneration (AMD) has also risen, emerging as an increasingly significant public health concern. This disease affects individuals over 55 years old and poses a threat to the high-resolution central vision necessary for essential human activities. There have been numerous hypotheses and investigations regarding the etiology of AMD. Research indicates that the onset of AMD is associated with factors such as oxidative stress, inflammatory responses, cell necrosis, and drusen. At present, the majority of treatments for neovascular age-related macular degeneration mainly involve injecting anti-VEGF antibodies to inhibit angiogenesis and delay the progression to blindness. In recent years, studies on the correlation between the complement pathway and AMD have been quite prevalent. Moreover, various genetic eye diseases have been treated using gene editing approaches. Hence, this review focuses on the pathogenesis of AMD and its related complement pathway, and provides an outlook on the application of gene editing therapy for AMD.

Tianshuo Zhang, Siyu Tang. Gene Editing: New Opportunities for the Treatment of Age-related Macular Degeneration. Frontiers in Medical Science Research(2025), Vol. 7, Issue 2: 35-44. https://doi.org/10.25236/FMSR.2025.070207.

[1] G. Yiu et al. (2015), Relationship of central choroidal thickness with age-related macular degeneration status. Am J Ophthalmol 159, 617-626.

[2] K. Kaarniranta et al (2020)., Mechanisms of mitochondrial dysfunction and their impact on age-related macular degeneration. Prog Retin Eye Res 79, 100858.

[3] J. M. T. Hyttinen, J. Viiri, K. Kaarniranta, J. Błasiak (2018), Mitochondrial quality control in AMD: does mitophagy play a pivotal role? Cell Mol Life Sci 75, 2991-3008.

[4] D. A. Ferrington, D. Sinha, K. Kaarniranta (2016), Defects in retinal pigment epithelial cell proteolysis and the pathology associated with age-related macular degeneration. Prog Retin Eye Res 51, 69-89.

[5] J. Hanus et al. (2013)., Induction of necrotic cell death by oxidative stress in retinal pigment epithelial cells. Cell Death Dis 4, e965

[6] Y. Murakami et al (2014).., Programmed necrosis, not apoptosis, is a key mediator of cell loss and DAMP-mediated inflammation in dsRNA-induced retinal degeneration. Cell Death Differ 21, 270-277

[7] J. Hanus, C. Anderson, S. Wang (2015), RPE necroptosis in response to oxidative stress and in AMD. Ageing Res Rev 24, 286-298.

[8] D. E. Christofferson, Y. Li, J. Yuan (2014)., Control of life-or-death decisions by RIP1 kinase. Annu Rev Physiol 76, 129-150

[9] M. Mochizuki, S. Sugita, K. Kamoi (2013), Immunological homeostasis of the eye. Prog Retin Eye Res 33, 10-27.

[10] M. Chen, C. Luo, J. Zhao, G. Devarajan, H. Xu (2019), Immune regulation in the aging retina. Prog Retin Eye Res 69, 159-172.

[11] C. Luo, M. Chen, H. Xu (2011), Complement gene expression and regulation in mouse retina and retinal pigment epithelium/choroid. Mol Vis 17, 1588-1597.

[12] H. L. Ramkumar, J. Zhang, C. C. Chan (2010)., Retinal ultrastructure of murine models of dry age-related macular degeneration (AMD). Prog Retin Eye Res 29, 169-190

[13] C. Pan et al (2021)., Lipofuscin causes atypical necroptosis through lysosomal membrane permeabilization. Proc Natl Acad Sci U S A 118.

[14] D. L. Nickla, J. Wallman (2010), The multifunctional choroid. Prog Retin Eye Res 29, 144-168.

[15] T. J. Heesterbeek et al (2020)., Complement Activation Levels Are Related to Disease Stage in AMD. Invest Ophthalmol Vis Sci 61, 18.

[16] A. Armento, M. Ueffing, S. J. Clark (2021), The complement system in age-related macular degeneration. Cell Mol Life Sci 78, 4487-4505.

[17] I. A. Bhutto et al. (2016), Increased choroidal mast cells and their degranulation in age-related macular degeneration. Br J Ophthalmol 100, 720-726.

[18] D. C. Mastellos et al(2015)., Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. Eur J Clin Invest 45, 423-440 

[19] X. Ren, J. Li, X. Xu, C. Wang, Y. Cheng (2016), IBI302, a promising candidate for AMD treatment, targeting both the VEGF and complement system with high binding affinity in vitro and effective targeting of the ocular tissue in healthy rhesus monkeys. Exp Eye Res 145, 352-358.

[20] G. J. Jaffe et al (2021).., C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. Ophthalmology 128, 576-586

[21] J. Yin et al (2022)., Safeguarding genome integrity during gene-editing therapy in a mouse model of age-related macular degeneration. Nat Commun 13, 7867.

[22] R. O. Bak, N. Gomez-Ospina, M. H. Porteus (2018), Gene Editing on Center Stage. Trends Genet 34, 600-611.

[23] F. Jiang, J. A. Doudna(2017), CRISPR-Cas9 Structures and Mechanisms. Annu Rev Biophys 46, 505-529.

[24] N. M. Gaudelli et al. (2017), Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature 551, 464-471.

[25] H. A. Rees, D. R. Liu (2018), Base editing: precision chemistry on the genome and transcriptome of living cells. Nat Rev Genet 19, 770-788.

[26] X. Liang, J. Potter, S. Kumar, N. Ravinder, J. D (2017). Chesnut, Enhanced CRISPR/Cas9-mediated precise genome editing by improved design and delivery of gRNA, Cas9 nuclease, and donor DNA. J Biotechnol 241, 136-146.

[27] S. Suh et al (2021).., Restoration of visual function in adult mice with an inherited retinal disease via adenine base editing. Nat Biomed Eng 5, 169-178

[28] M. L. Maeder et al (2019)., Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. Nat Med 25, 229-233.

[29] E. Piotter, M. E. McClements, R. E. MacLaren(2021), Therapy Approaches for Stargardt Disease. Biomolecules 11.

[30] D. Athanasiou et al (2018)., The molecular and cellular basis of rhodopsin retinitis pigmentosa reveals potential strategies for therapy. Prog Retin Eye Res 62, 1-23.